• 客服專區
  • 登入
  • 註冊
產業簡報

events近期活動

      keyword關鍵議題

      expert熱門專家

        POP REPORT熱門文章

        i卡會員

        歡迎免費加入,享有多項免費權益!

        >

        PRESENTATIONS主題推薦

        POPULAR熱門專區

        FIEK360|Taiwan Immuno-oncology Therapies: Status Quo and Outlook
        • 2022/09/29
        • 2141
        • 84

        簡報大綱

        Immuno-oncology (aka IO) has been a critical sector of cancer therapy since the 1990s. There are two subsectors that especially catch the eyes of investors these years, they are immune checkpoint inhibitors (aka ICI) and immune cell therapies.

        So far, there are nine ICIs approved by FDA since 2011, seven of them belong to  PD1/PDL1 series, one belongs to CTLA-4 and the latest approved targets LAG3. Most of these ICIs are used in combination with the other therapeutics agents because ICIs only work well on about 20~30% of the cancer population.
        On the other hand, we have seen the magic of CAR-T (one of the immune cell therapies).  This living drug can even cure the deadly disease that humans never thought that they would be capable of vanquishing.

        Though powerful, there are still unmet needs to be fulfilled and adverse side effects to be overpowered for ICIs and immune cell therapies. In this talk, I would like to deliver.

        1. Briefing on the global IO therapies industry & trends
        2. Overview of domestic industry on IO development
        3. Discuss the IO development strategies for the Taiwan biotech industry
           

        簡報內容

        Taiwan Immuno-oncology Therapies: Status Quo and Outlook
        NO.1
        Glossary
        NO.2
        NO.3
        IO therapy occupies 1/3 of global oncology drug market
        NO.4
        Top 3 IO Therapies in 2025: Ab-based Targeting Drugs, ICI & Immune cell therapy
        NO.5
        ICI Competing Landscape - USA, EU & Japan
        NO.6
        Approved gene-modified immune cell therapy
        NO.7
        NO.8
        iPSC for off-the-shelf product attracts investment from MNC
        NO.9
        Breakthrough CGT companies - off-the-shelf product, vector technology, scale-up production
        NO.10
        NO.11
        Status Quo of Taiwan IO Sector- 17 products involved in IO Clinical Trial
        NO.12
        Cell therapy is the main theme of Mid- & late-stage of clinical development
        NO.13
        Next Generation Cell therapy Companies of Taiwan
        NO.14
        NO.15
        Take home message …
        NO.16
        thank you
        NO.17

        推薦閱讀